Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02609048 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT02609048 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 41 participants.
The verdict
NCT02609048, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effect of seladelpar (MBX-8025) on alkaline phosphatase (AP) levels in participants with primary biliary cirrhosis (PBC).
Interventions
- DRUG Placebo Comparator
- DRUG Experimental: Seladelpar 50 mg
- DRUG Experimental: Seladelpar / MBX-8025 200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2015-11-04 |
| Est. Completion | 2016-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02609048
The ClinicalTrials.gov registry entry for NCT02609048 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Comparator is the first listed.
NCT02609048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02609048 about?
NCT02609048 is a clinical study titled "Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)". The primary objective of this study is to evaluate the effect of seladelpar (MBX-8025) on alkaline phosphatase (AP) levels in participants with primary biliary cirrhosis (PBC).
What is the current status of trial NCT02609048?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2015-11-04. Estimated completion is 2016-07-01.
What interventions are being tested in trial NCT02609048?
The interventions under investigation include: Placebo Comparator (DRUG), Experimental: Seladelpar 50 mg (DRUG), Experimental: Seladelpar / MBX-8025 200 mg (DRUG).
Who is sponsoring clinical trial NCT02609048?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.